Subsidy Information and Financing Scheme MSHLEpcoritamab Concentrate For Solution For Injection 4 mg/0.8 mL For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBC... See all × MSHLEpcoritamab Concentrate For Solution For Injection 4 mg/0.8 mL For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. MSHLEpcoritamab Solution For Injection 48 mg/0.8 mL For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBC... See all × MSHLEpcoritamab Solution For Injection 48 mg/0.8 mL For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Drug Guidance for Subsidy 16/09/2025 Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy NRThe Ministry of Health’s Drug Advisory Committee has not recommended epcoritamab for inclusi... See all × 16/09/2025 Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy NRThe Ministry of Health’s Drug Advisory Committee has not recommended epcoritamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The decision for epcoritamab was based on the uncertainties surrounding its magnitude of clinical benefit, unfavourable cost-effectiveness compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for epcoritamab are provided in the Annex.
Post Marketing Information PAC 02/10/2024 Patient Card: Safety Information about Epkinly™ (epcoritamab)
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Epkinly Concentrate For Solution For Injection 4 mg/0.8 mL National Cancer Centre Epkinly Solution For Injection 48 mg/0.8 mL National Cancer Centre
SUBCUTANEOUS Select a brand starting with the letter: E EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML [SIN17106P] EPKINLY SOLUTION FOR INJECTION 4MG/0.8ML [SIN17105P]